Navigation Links
Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
Date:5/15/2013

NEW YORK, May 15, 2013 /PRNewswire/ -- Edgemont Capital Partners ("Edgemont"), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical Research ("Vince and Associates") in its sale to Altasciences Group.  Vince and Associates manages complex early development clinical drug trials at its state-of-the-art research facility in Overland Park, Kansas.  The transaction highlights growing demand from large pharmaceutical and biotechnology companies for conducting early development studies in patient populations. Terms of the deal were not announced.

(Logo: http://photos.prnewswire.com/prnh/20130117/NY43188LOGO )

This is the ninth transaction completed by Edgemont on behalf of clinical research site services companies and one of the largest to date, further establishing Edgemont as the leading M&A advisor to clinical research site companies. Prior transactions completed by Edgemont include the sale of Miami Research Associates, Inc. to QPS, LLC, the sale of California Clinical Trials, Inc. to Parexel Inc., and the sale of Lifetree Clinical Research, LLC to CRI Worldwide, LLC, among others.

Vince and Associates is a leader in the successful recruitment and retention of special patient populations in complex early development clinical drug trials.  The company's approach utilizes study teams led by highly experienced principal investors who are intimately involved in all aspects of the clinical trial process.  The transaction with Altasciences is a further reflection of the significant industry demand for specialized outsourcing services on the part of large pharmaceutical and biotechnology companies.

We are seeing strong acquisition interest in sophisticated site services companies like Vince and Associates that have unique and established access to highly desirable patient populations and a proven track record of research excellence," said David K. Blume , co-founder and Managing Director at Edgemont.  "Access to these populations is critical to the drug development success of pharmaceutical and biotechnology companies, and represents tremendous value."

Altasciences is owned by Kilmer Capital Partners, which also owns Algorithme Pharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and Algorithme Pharma operate with a common mission to provide the highest quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.

About Edgemont Capital Partners

Edgemont Capital Partners, L.P. (www.edgemontcapital.com) is a specialty investment bank focused on the advisory needs of healthcare companies worldwide. The firm's deep healthcare industry knowledge, extensive relationship network and substantial transaction expertise allows Edgemont to address healthcare companies' strategic advisory (M&A) and financing needs with great success. Edgemont Capital Partners, L.P. provides mergers and acquisition advisory, restructuring advisory, board advisory, valuation and private placements services. Investment banking services are provided by Edgemont Capital Partners, L.P., a registered broker-dealer and member of FINRA and SIPC.

About Vince & Associates Clinical Research

Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for more than a decade. Proud to be recognized in the industry as a "Center of Research Excellence", Vince & Associates has become a premier clinical research site by utilizing The Physician Research Model(R) of operation where study teams are led by highly experienced principal investigators intimately involved in all aspects of the clinical trial process.

Vince & Associates recently opened a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This new unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials, from the safety and security of the controlled access unit to the added features of a movie theater and game rooms.


'/>"/>
SOURCE Edgemont Capital Partners, L.P.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Fewer Venture Capital Dollars Invested Into Life Sciences Companies In Q1 2013, According To The MoneyTree Report
2. New Company Abyrx, Inc. Acquires Substantially All of the Assets of Orthocon and DRG; Fully-Capitalizes to Accelerate Growth of Exciting New Biosurgical Product Portfolio
3. BioRestorative Therapies Appoints ProActive Capital Group as Capital Markets & Digital Media Advisor
4. Foundation Venture Capital Group Invests In Company Developing Implantable Meniscus for Knee Repair
5. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
6. Creekridge Capital Announces Record Volume
7. Carolina Piedmont Capital To Exhibit At Raleigh Business Expo
8. Express Scripts Recommends Rejection of TRC Capitals "Mini-Tender" Offer
9. MedFocusCapital Partners Announces See.Hear.Live.Better! Alliance
10. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
11. GC-Rise Attracts Attention in Health Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):